However, other anti-TNF-alpha agents such as certolizumab pegol (CZP) have limited evidence for ocular involvement in BD patients, with data from small case series or heterogeneous populations with different diseases focused in spondyloarthritis [27,28,29,30]. Here, TNF is linked to Behcet disease.